|
Volume 272, Number 25,
Issue of June 20, 1997
pp. 15993-16001
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
Activation Transcription Factor 1 Involvement in the Regulation
of Murine H-2Dd Expression*
(Received for publication, April 23, 1996, and in revised form, March 12, 1997)
Nobuhisa
Ishiguro
,
G. Dalon
Brown
and
Daniel
Meruelo
From the Department of Pathology and the Kaplan Cancer Center, New
York University Medical Center, New York, New York 10016
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
ABSTRACT
Resistance to radiation leukemia virus-induced
leukemia is correlated with an increase in H-2D expression on the
thymocyte surface. Recently, it has been shown that elevated
H-2Dd expression on the infected thymocyte is a
result of elevated mRNA transcription and that the transcriptional
increase is correlated with elevated levels of a DNA binding activity,
H-2 binding factor 1 (H-2 BF1), which recognizes the 5 -flanking
sequences (5 -TGACGCG-3 ) of the H-2Dd gene. This
target for transcription factor binding has been found to be identical
in the 5 -regulatory region of 12 rodent class I genes, nine of which
have been shown to be functional genes. Furthermore, this
cis-element is found 5 of 20 primate class I genes (15 human genes), seven of which are known to be functional. Here, we
demonstrate that activation transcription factor 1 (ATF-1) is one
component of H-2 BF1. In addition, the levels of ATF-1 mRNA in uninfected and radiation leukemia virus-infected thymocytes parallel those of H-2Dd mRNA, and therefore, it
is suggested that ATF-1 up-regulates the transcription of the
H-2Dd gene after radiation leukemia virus infection
of thymocytes. Transfection experiments also demonstrate that ATF-1
activates a reporter plasmid that contains the H-2 BF1 motif, but not a reporter lacking this motif. This is the first demonstration of the
interaction of ATF-1 with 5 -regulatory sequences of major histocompatibility complex class I genes.
INTRODUCTION
The MHC1 encodes highly polymorphic
cell-surface antigens that play an important role in recognition and
elimination of virus-infected or neoplastic cells by the immune system
(1, 2). Murine H-2 class I gene expression has been shown to
be significantly altered in thymic cells after both radiation leukemia
virus (RadLV) infection and RadLV-induced transformation (3). Early
studies using H-2 congenic mouse strains demonstrated that
the H-2Dd locus of the MHC is sufficient to result
in resistance to RadLV-induced thymoma development (4). Following
infection of resistant mouse strains, there is a rapid increase in the
level of Dd antigen on the surface of infected thymocytes.
The immune system of resistant strains recognizes the infected cells,
and a cell-mediated immune response is detectable in vitro;
no such immune response is seen in susceptible hosts (5). Soon
thereafter, the virus-infected cells are eliminated from the resistant
mice, and tumors arise in only a very small percentage of these animals
(5). In the susceptible mouse strains (mice carrying the
H-2D gene of a haplotype other than Dd),
the levels of H-2 expression are variable, no cell-mediated immune
response is generated, and a high percentage of infected mice go on to
develop thymomas. These observations clearly indicate the importance of
immunosurveillance in determining the phenotypic response (resistance
versus susceptible) following RadLV infection and potential
tumorigenesis.
More recently, we have examined the stimulation of H-2Dd
expression at the molecular level. It was shown that infection by RadLV
results in the increased transcription of H-2 gene(s) and a
concomitant increase in H-2Dd antigen on the surface of the
thymocytes (6). Also detectable in nuclear extracts prepared from
infected thymocytes is an increased DNA binding activity that
specifically recognizes the sequence 5 -TGACGCG-3 in the 5 -flanking
region of the H-2Dd gene. This
trans-acting factor has been termed H-2 binding factor 1 (H-2 BF1). The importance of this CRE-like cis-factor in
class I regulation was first noted by Israel et al. (7) in
1989 and subsequently by Dey et al. (8), Saji et
al. (9), and Nobunaga et al. (10) in 1992. Although, in
these studies, the biological function of this cis-element
in class I regulation was suggested, the trans-factor(s)
that bound to this element were not identified. We have previously
shown that proteins of 27 and 65 kDa bind to this
cis-sequence as determined by UV photocross-linking studies (10).
After an exhaustive search of GenBankTM sequences, we have shown that
this target binding sequence is present in the 5 -regulatory region of
many class I genes. Notable among the findings is that this
cis-element is identical in 17 out of 22 class I genes that have been shown to be functional, i.e. not pseudogenes, by
transfection analysis. The extraordinary conservation of this sequence
across evolutionary lines emphasizes its potential importance in the regulation of expression of the major histocompatibility antigens.
In the experiments described here, we have screened a plasmid cDNA
expression library using the yeast one-hybrid system (11). Numerous
cDNA clones have been isolated, and one group of these cDNA
clones is shown to encode activation transcription factor 1 (ATF-1).
Using gel supershift assays, ATF-1 is demonstrated to be one component
of the in vivo H-2 BF1 complex. Several facts support this
evidence. Both human and mouse ATF-1 are known to bind to the CRE
binding motif (12, 13), which is similar to the H-2 BF1 binding
sequence. Murine ATF-1 has a molecular mass of 29 kDa, comparable to
the 27-kDa protein observed in UV cross-linking studies of H-2 BF1
(10). The expression level of mRNA encoding ATF-1 closely parallels
that of H-2 mRNA in both RadLV-infected and normal
thymuses. Transfection experiments also demonstrate that ATF-1
activates a reporter plasmid that contains the H-2 BF1 motif. These
observations suggest that ATF-1 is involved both in the normal
regulation of H-2 expression and in the stimulation of transcription
from the H-2Dd gene after RadLV infection of mouse
thymocytes.
MATERIALS AND METHODS
Mice, Virus, and Cells
B10.T(6R) mice resistant to RadLV
were purchased from The Jackson Laboratory (Bar Harbor, ME) and bred at
the New York University Medical Center. RadLV was prepared as cell-free
extracts of thymomas induced by intrathymic injection of similarly
passaged RadLV (14). Preparation of infected thymocytes for RNA
preparation and nuclear extraction was as described (10). Cell lines
were derived from RadLV-induced thymomas and maintained as described by
Bach and Meruelo (15). F9 cells were maintained in Dulbecco's modified Eagle's medium plus 10% calf serum on gelatin-coated dishes.
cDNA Library Preparation and Screening
cDNA plasmid
screening using the one-hybrid system was performed by the method of
Wang and Reed (11). Briefly, cDNA was synthesized from the mRNA
isolated from a RadLV-induced, thymoma-derived cell line (15) using the
Superscript plasmid system (Life Technologies, Inc). The product was
directionally cloned into the SalI-NotI sites of
the yeast expression vector pPC86. The ligation products were
introduced by electroporation (Bio-Rad) into Escherichia coli strain DH10B (Life Technologies, Inc.). The cDNA library was composed of 2.6 × 106 independent clones with an
average insert size of 1.5 kb. The reporter plasmid pRS315HIS-#7×4,
derived from pRS315HIS (11), contained four tandem copies of the H-2
BF1 binding site (10) inserted into the BamHI site upstream
of the GAL1 minimal promoter linked to the HIS3 gene. The
yeast strain yWAM2 was first transformed with the pRS315HIS-#7×4
plasmid by the lithium acetate method (11) and selected on
leucine-deficient medium. This yeast strain was then transformed with
the RadLV-transformed cell line cDNA described above. The
transformants were plated on synthetic dextrose medium (16) without
histidine (but including leucine and tryptophan) and incubated for 4 days at 30 °C. Colonies on these plates were transferred by replica
plating onto synthetic dextrose plates without histidine, leucine, and
tryptophan and incubated for another 4 days. Viable yeast colonies were
picked and grown in synthetic dextrose medium without histidine,
leucine, and tryptophan. Plasmid DNAs were isolated (16) and
analyzed.
Northern Blot Analysis
Total RNA was isolated according to
the acid guanidinium thiocyanate-phenol-chloroform extraction method of
Chomczynski and Sacchi (17). Northern blotting and hybridization were
carried out as described previously (18). Hybridization probes used were H-2 IIa(sub), a broadly cross-reactive cDNA subclone of H-2 IIa lacking the repetitive sequences (19, 20); ATF-1, excised by
BamHI and HindIII from the ATF-1A clone (see Fig.
1); and -actin (21).
Fig. 1.
A, schematic representation of the
sequences for the previously published mouse ATF-1 cDNA (13) and
ATF-1A and ATF-1B cDNAs. The solid bar of each cDNA
indicates the open reading frame. Small cross-hatched bars
indicate potential polyadenylation signals (AATAAA and TATAAA) (13).
H and B identify HindIII and
BamHI restriction sites, respectively. The hatched
bar, excised by BamHI and HindIII, indicates
the probe used for Northern analysis. The open box shows the
structure of the ATF-1 protein; BASIC and ZIP indicate the basic region and leucine zipper of mouse ATF-1.
B, sequence of the 5 -noncoding regions of ATF-1A and
ATF-1B. The 5 -ends of ATF-1 and ATF-1A are indicated on the longer
ATF-1B. The beginning of translation (ATG) is also indicated.
C, sequence of the 3 -noncoding regions of both clones.
Single base pair deletions are indicated by asterisks;
insertions are boxed; and a single base pair substitution is
indicated in parentheses above the ATF-1B sequence. The
3 -end of ATF-1A is indicated. Potential polyadenylation signals are
indicated in boldface.
[View Larger Versions of these Images (35 + 23K GIF file)]
Gel Mobility Shift Assays
Nuclear extracts were prepared
from thymocytes of both RadLV-infected and normal mice of the B10.T(6R)
strain as well as from the RadLV-induced, thymoma-derived cell line
according to Dignam et al. (22). Protein concentration of
extracts was measured by the Bio-Rad protein assay. The following
oligonucleotide and its complement containing the H-2 BF1 motif were
synthesized: 5 -CACTGATGACGCGCTG-3 . Complementary oligonucleotides
containing the mutant H-2 BF1 motif were also synthesized:
5 -CACTGATGAAGAGATG-3 . Complementary oligonucleotides containing the CRE found in the T-cell
receptor V promoter were also synthesized (13):
5 -ACAGTGACATCACTAA-3 . Equimolar amounts of these oligonucleotides
were annealed with their complement and 5 -end-labeled by T4
polynucleotide kinase (New England Biolabs Inc., Beverly, MA). The
labeled oligonucleotides were incubated with either the nuclear
extracts or the in vitro translation products and
electrophoresed through nondenaturing 5% polyacrylamide gels with
0.5 × TBE (Tris borate/EDTA) at 150 V for 2 h (Fig.
2A) or for 7 h (Figs. 2B and 3-5) (10).
Fig. 2.
A, gel mobility and competition assays
of in vitro translation products of ATF-1A. End-labeled,
double-stranded H-2 BF1 binding motif (WT) oligonucleotide
(1 × 105 cpm) was incubated with in vitro
translation products. Lane 1, in vitro products
of the pSG5 vector alone; lane 2, in vitro
products of ATF-1A cDNA subcloned into pSG5; lanes 3-5,
unlabeled, double-stranded oligonucleotide (H-2 BF1 motif) at 50-, 100-, and 150-fold molar excess, respectively, used as a competitor
prior to the addition of radiolabeled probes; lanes 6-8,
unlabeled, double-stranded oligonucleotide (mutant H-2 BF1 motif
(MUT)) at 50-, 100-, and 150-fold molar excess,
respectively, used as a competitor. F indicates free
radiolabeled oligonucleotide probes. Samples were electrophoresed through nondenaturing 5% polyacrylamide gels with 0.5 × TBE at 150 V for 2 h. B, gel mobility and competition assays
of nuclear extracts. End-labeled, double-stranded wild-type
oligonucleotide (1 × 105 cpm) was incubated with
nuclear extracts. Lane 1, 1 µg of nuclear extracts from
the RadLV-induced, thymoma-derived cell line; lanes 2-4,
unlabeled oligonucleotide (WT) at 50-, 100-, and 150-fold molar excess, respectively, used as a competitor prior to the addition
of radiolabeled probes; lanes 5-7, unlabeled
oligonucleotide (MUT) at 50-, 100-, and 150-fold molar
excess, respectively, used as a competitor. Samples were
electrophoresed through nondenaturing 5% polyacrylamide gels with
0.5 × TBE at 150 V for 7 h.
[View Larger Version of this Image (62K GIF file)]
Fig. 3.
Gel mobility assays using synthesized
oligonucleotides corresponding to the H-2 BF1 binding motif.
End-labeled wild-type oligonucleotide (1 × 105 cpm)
was incubated with either in vitro translation products or
nuclear extracts. Lane 1, 1 µg of nuclear extracts from
the RadLV-induced, thymoma-derived cell line; lane 2,
in vitro products of ATF-1A cDNA subcloned into pSG5;
lane 3, in vitro products of the pSG5 vector
only.
[View Larger Version of this Image (29K GIF file)]
In Vitro Protein Synthesis
ATF-1A cDNA was subcloned
into pSG5 (Stratagene, La Jolla, CA), and the ATF-1 protein was
synthesized in vitro by the TNT T7 coupled reticulocyte
lysate system (Promega, Madison, WI) according to the manufacturer's
instructions. Unmodified pSG5 was also used for in vitro
translation as a negative control.
Gel Mobility Supershift Assays
For gel supershift assays,
specific monoclonal antibodies were mixed with binding reactions (as
described above) of the labeled oligonucleotides and nuclear extracts,
incubated for 1 h on ice, and loaded onto the gel. Specific
monoclonal antibodies against ATF-1 (products sc-270x and sc-243x),
ATF-2 (product sc-187x), and c-Jun (product sc-45x) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA).
Plasmid Constructs and Transfection Assays
The plasmid
pRc/RSV/ATF-1 expression vector was generated by subcloning ATF-1A
cDNA into pRc/RSV (Invitrogen, Carlsbad, CA). The plasmid
pRc/RSV/1-FTA contained the ATF-1A cDNA in the antisense orientation, but was otherwise identical to pRc/RSV/ATF-1. The plasmids
 65CAT and  122CAT, containing sequences of the mouse H-2Dd gene from positions 65 to +20 and from
positions 122 to +20, respectively, linked to the gene for
chloramphenicol acetyltransferase, were obtained from Dr. I. Stroynowski (23). The mammalian expression vector for the catalytic
subunit of the cAMP-dependent protein kinase,
RSV-CHO-PKA-C version 2, was obtained from Dr. R. A. Maurer (24).
Cells (5 × 105 F9 cells/10-cm dish) were transfected
by the LipofectAMINE method (Life Technologies, Inc.) according to the
manufacturer's instructions. The DNAs for each transfection contained
5 µg of reporter plasmid ( 65CAT or  122CAT), 5 µg of
RSV-CHO-PKA-C version 2 or pBluescript II SK+
(Stratagene), 5 µg of pRc/RSV/ATF-1 or pRc/RSV/1-FTA, and 1 µg of
pSV- -galactosidase control vector (Promega) as an internal reference. The total amount of plasmid DNA was 16 µg/transfection. After 40 h, extracts were prepared, and chloramphenicol
acetyltransferase assays were performed as described (25). Acetylated
chloramphenicol was measured using the NIH Image program (Version 1.60)
from autoradiographed film and corrected for -galactosidase activity
to normalize for transfection efficiency (26).
RESULTS
The H-2 BF1 Binding Site Is Present 5 of MHC Class I Genes of Many
Species
Class I sequences in GenBankTM were searched for the
presence of the H-2 BF1 target element by using GCG Version 8 software (Genetics Computer Group, Madison, WI). Eighteen murine H-2
class I gene sequences were identified that contain at least 150 bp of
5 -flanking sequence data. Of these 18, 11 encode classical transplantation antigens, while seven are either of the TLa
or Qa families. All 10 genes, in addition to
Dd, that encode transplantation antigens contain in
their 5 -sequence the identical 7-bp sequence identified as the binding
target for H-2 BF1 (Table I). Eight of these 11 transplantation genes have been found to be active following
transfection into cells. The seven H-2 genes not containing
this cis-element are in the TLa/Qa families
(27-31). Furthermore, two of the genes have been shown to be
pseudogenes, and none of the seven have been demonstrated to be
functional after transfection. Four rat class I genes were located that
contain significant sequence data 5 of the gene. One of these,
RT 1.C, has been shown to be functional and does indeed
contain the H-2 BF1 target sequence (32). Of the three remaining
isolates, two are functional but are TLa-like (33, 34), and
the third is a pseudogene (35). Two swine genes were also identified
and found to contain the binding sequence; one of these has been shown
to be functional, while the other has not (36, 37).
Table I.
Comparison of the 5 -regulatory regions of class I MHC genes
|
| Gene |
Sequence |
Source |
|
| Murine class I |
| H-2
Dd a |
GGGACACTGATGACGCGCTGGCAGGTC |
65
|
| Db, a |
...........................
|
66
|
| Dka |
.......A...................
|
67
|
| Kb, a |
C........T........A.T...C.. |
68
|
| Lda |
...........................
|
30
|
| Dqa |
...........................
|
69b
|
| Dsa |
...........................
|
b
|
| Ksa |
C........T........A.T...C.. |
b
|
| Dp |
C..GACACTA..............A.. |
70
|
| Kk |
C........T........A.T...C.. |
71
|
| Kw28 |
C........T........A.T...C.. |
60
|
| Rat class I |
| RT
1.Ca |
C...T.............A...AT.. |
32 |
| Swine
class I |
| SLA |
| PD1a |
C....
..CG.......ACCC...C.T |
36 |
| d
haplotype |
C.......CG.......GCCC..CT.. |
37 |
| Human class I
|
| HLA
|
| Cw3a |
.AATG...C........TCCC..AT.. |
72
|
| B27a |
A...T...CG.......TCCC..TT.. |
73
|
| Cw1Ba |
T.A.T...C........TCCC..AT.. |
74
|
| Cw2Ba |
T.A.T...C........TCCC..AT.. |
74
|
| B7a |
A...T...CG.......TCCC..CT.. |
46
|
| B51a |
A...T...CG.......TCCC..TT.. |
46
|
| Bw57a |
A...T...CG.......TCCC..TT.. |
75
|
| B |
A...T...CG.......TCCC..AT.. |
76
|
| C1 |
T.A.T...C........TCCC..AT.. |
76
|
| B51-cd3.3 |
CA.GT...CG.......TCCC..TT.. |
77
|
| B35 |
A...T...CG.......TCCC..TT.. |
78
|
| B |
A...T...CG.......TCCC..TT.. |
79
|
| CwBL18 |
T.A.T...C........TCCCA.TTC. |
80
|
| Cw5 |
T.A.T...C........TCCCC.AT.. |
80
|
| JY328 |
.AATG...C........TCCC..AT.. |
81
|
| Gorilla class I |
| Gogo:
|
| McB26 |
A...T...CG.......TCCC..TT.. |
79
|
| SbB16 |
A...T...CG.......TCCC..TT.. |
79
|
| Chimp class I |
| Patr
|
| K1811 |
A...T...CG.......TCCC..TT.. |
79
|
| T1725 |
A...T...CG.......TCCC..TT.. |
79
|
| Orangutan class I |
| Popy
C1524 |
CA..T...CG.......TCCC..TT.. |
79 |
|
|
a
These genes have been shown to be functional by
transfection and expression.
|
|
b
G. D. Brown D. R. Morris, and D. Meruelo (1997) Eur.
J. of Immunol., in press.
|
|
The data bank search resulted in 24 human class I genes containing
sufficient sequences 5 of the coding region for examination. Thirteen
of these were found to contain the identical sequence that serves as a
target for H-2 BF1 and activates transcription in the mouse; five of
these have been shown to be functional (Table I). Of the 11 that do not
contain the sequence, two are pseudogenes (38-40), two are
HLA-A genes (41, 42), two are non-HLA-A/B/C genes
that resemble the H-2 TLa/Qa genes of the mouse (43, 44), and the final five have been shown to be functional class I genes (45-47). The isolates of HLA-E and HLA-Aw24 are
apparently functional in the thymus (42, 43). All of the substitutions
within the target sequence occur in either the first or last base of
the septumer, none in the "core" of 5 bases. Other primate
sequences that contain the H-2 BF1 target are found in the gorilla,
chimpanzee, and orangutan (Table I). These latter sequences, however,
were not isolated as part of an intact class I gene, i.e.
these promoter regions were cloned following polymerase chain reactions
on genomic DNA from these species. The genes to which they are linked
have not been isolated and therefore not tested for functionality. Several other sequences from primates, including human, have been isolated in this manner and do not contain the binding sequence. Until
the genes themselves are isolated and examined, the significance of
this observation is difficult to access. In conclusion, however, of the
class I genes that have been shown to be functional, 17 out of 22 do
contain the H-2 BF1 cis-target sequence.
Cloning of ATF-1 Using the One-hybrid System in Yeast
The
cDNA library was prepared from RNA isolated from a RadLV-induced
B10.T(6R) thymoma cell line as described under "Materials and
Methods." More than 10 library equivalents (3.5 × 107 yeast colonies) were screened, and 49 cDNA plasmids
were recovered and analyzed. From the partial sequencing of clones and
the digestion patterns using a number of restriction enzymes, 22 plasmids were found to have homology to the cDNA of mouse
ATF-1 (13). Based on the insert size, these clones were
divided into two groups: one group with ~1.5-kb inserts and another
group with ~2.4-kb inserts. The longest insert of each group was
subcloned into pBluescript II SK+ and SK
(Stratagene) and sequenced by the single chain termination method of
Sanger et al. (48) using Sequenase (U. S. Biochemical
Corp.). The 1472-bp nucleotide cDNA insert of the first group,
referred to as ATF-1A, was identical to mouse ATF-1 (13) except that ATF-1A had an additional 201 bp in the 5 -noncoding region and a
truncation of ~760 bp in the 3 -noncoding region (Fig.
1B). Two single base pair insertions were
also found in the 3 -noncoding region. The second group, referred to as
ATF-1B, contained a 2372-bp nucleotide insert. The coding region was
found to be identical to the mouse ATF-1 cDNA. The 3 -noncoding
sequence differed in that in addition to the two single base pair
insertions mentioned above, one more single base pair insertion was
seen, and three single base pair deletions and one single base pair
substitution were identified (Fig. 1C). ATF-1B had 258 bp in
the 5 -noncoding region not seen in ATF-1; the 201-bp overlap between
ATF-1A and ATF-1B is identical, however. These observations would
indicate that most probably both ATF-1A and ATF-1 are not complete
reverse transcripts. The difference in the size of ATF-1A and ATF-1B in the 3 -end could be explained by utilization of two different polyadenylation sites, thereby generating mRNAs of ~1.5 and
~2.4 kb (13, 49, 50). Differences in 1 or 2 bases in the 3 -noncoding region may represent divergence between BALB/c mice, the strain used in
the generation of the hybridoma used by Lee et al. (13), and
the B10.T(6R) mice used in these experiments. Both cDNAs, ATF-1A
and ATF-1B, have only one long open reading frame, which encodes
activation transcription factor 1. This protein has a molecular mass of
29 kDa and has been grouped into the bZIP (basic leucine zipper) family of transcription factors
(51) (Fig. 1).
ATF-1 Binds to the H-2 BF1 Binding Motif
Binding to the
double-stranded H-2 BF1 oligonucleotide was detected in in
vitro translated ATF-1A (Fig. 2A,
lane 2), whereas no binding of the in vitro
products of the pSG5 vector alone was seen (lane 1). This is
further supported by the fact that these clones were isolated using the
one-hybrid system in yeast, where recognition of the
cis-element contained in the reporter plasmid by the
expressed cDNA product is a prerequisite for isolation. Binding to
the CRE consensus oligonucleotide was also detected in nuclear extracts
from the cell line and in vitro translated ATF-1A (data not
shown). Specificity of binding was demonstrated by the competition
assays. The addition of unlabeled H-2 BF1 oligonucleotides (WT) at 50-, 100-, and 150-fold molar excess resulted in a
reduction of binding activity (Fig. 2A, lanes
3-5, respectively). The addition of mutant oligonucleotide
(MUT) at 50-, 100-, and 150-fold molar excess had little
effect on binding (Fig. 2A, lanes 6-8,
respectively).
Parallel experiments were performed using nuclear extracts from the
RadLV-induced, thymoma-derived cell line (Fig. 2B). Four bands (bands A-D) were observed in the absence of competitor (Fig. 2B, lane 1). Specificity of binding was
demonstrated by the competition assays. The addition of unlabeled H-2
BF1 oligonucleotide (WT) at 50-, 100-, and 150-fold molar
excess resulted in a reduction of all four bands (Fig. 2B,
lanes 2-4, respectively). On the other hand, the addition
of mutant oligonucleotide (MUT) at 50-, 100-, and 150-fold
molar excess had little effect on bands A-C and partial reduction of
band D (Fig. 2B, lanes 5-7, respectively). The
differences in migration patterns are a result of differing gel
electrophoresis times (see figure legends).
The ATF-1 Homodimer Is One Component of H-2 BF1 in Vivo
To
directly compare the migration of DNA-protein complexes seen in the gel
shift analysis, the bound cell line extract and in vitro
products were run on the same nondenaturing 5% polyacrylamide gel
(Fig. 3). Four bands (bands A-D) were observed in the
cell line nuclear extract as described above (Fig. 3, lane
1). The same four bands were subsequently observed in thymocyte
extracts from both RadLV-infected and normal B10.T(6R) mice (see Fig.
5). The in vitro products of ATF-1A in lane 2 comigrated with band C in lane 1. No binding was observed in
the in vitro products of the pSG5 vector only (Fig. 3,
lane 3). Because it has been shown that ATF-1/CREB proteins
usually form either homodimers or heterodimers (51), band C in
lane 1 is probably the ATF-1 homodimer since only one
cDNA was included in the translation reaction. When the
[35S]methionine-labeled in vitro translation
products of ATF-1A were analyzed on denaturing SDS-polyacrylamide gels,
some truncated (<27 kDa) and elongated (>27 kDa) forms were observed
(data not shown). Therefore, it is not surprising that the binding of
in vitro translated ATF-1A (Fig. 3, lane 2) did
not result in a single discrete band.
Fig. 5.
Comparison of binding activity among normal
thymocytes, RadLV-infected thymocytes, and the RadLV-induced,
thymoma-derived cell line. 1 µg of nuclear extracts from every
preparation was incubated with end-labeled wild-type oligonucleotide
(1 × 105 cpm). Lanes 1 and 2,
normal thymocytes of B10.T(6R) mice; lanes 3 and
4, RadLV-infected B10.T(6R) mice; lanes 5 and
6, the RadLV-induced, thymoma-derived cell line.
[View Larger Version of this Image (63K GIF file)]
To demonstrate that ATF-1 is indeed a component of H-2 BF1 in the
thymocyte, we examined the effect of two anti-ATF-1 antibodies on the
mobility of the H-2 BF1·DNA complex. Antibodies to two other closely
related, but distinct members of the leucine zipper family of
transcriptional activators were used as negative controls (anti-c-Jun
and anti-ATF-2). Supershift of bands A-C with one anti-ATF-1 antibody
(Santa Cruz Biotechnology product sc-270x) was observed (Fig.
4, lane 2). With another anti-ATF-1 antibody (Santa Cruz Biotechnology product sc-243x), only band C was shifted up
(Fig. 4, lane 3). On the other hand, anti-c-Jun and
anti-ATF-2 antibodies had no effect on the migration of the complex
(Fig. 4, lanes 4 and 5, respectively). As we have
shown in Fig. 3, band C is most probably the ATF-1 homodimer. The
resulting supershift of band C with both anti-ATF-1 antibodies
confirmed this. These data demonstrate that the H-2 BF1 complex,
present in normal thymocytes and at elevated levels in RadLV-infected
and RadLV-induced thymoma cell lines, contains ATF-1 as one of the
components.
Fig. 4.
Gel supershift assay with anti-ATF-1,
anti-c-Jun, and anti-ATF-2 antibodies. Nuclear extracts (1 µg)
from the RadLV-induced, thymoma-derived cell line were incubated with
end-labeled, double-stranded oligonucleotide (1 × 105
cpm) containing H-2 BF1 target sequences. Lane 1 had no
antiserum added. Specific antibodies against ATF-1 (lane 2,
sc-270x; lane 3, sc-243x), c-Jun (lane 4,
sc-45x), and ATF-2 (lane 5, sc-187x) were mixed with
parallel binding reactions, incubated for 1 h on ice, and loaded
onto gel. All antibodies were purchased from Santa Cruz Biotechnology.
Supershifts of the H-2 BF1 complex with anti-ATF-1 antibodies were
observed: an asterisk (*) in lane 2 and
double asterisks in lane 3.
[View Larger Version of this Image (111K GIF file)]
Based on the gel shift data using the cell line nuclear extracts, the
H-2 BF1 complex is composed of four forms (bands A-D; Figs.
2B and 3-5). As described above, band C represents the
ATF-1 homodimer. The following results led to the conclusion that band A is the CREB homodimer and that band B is the ATF-1/CREB heterodimer. 1) With specific anti-CREB-1 antibody, band A was totally and band B
was partially shifted up; 2) the migration of in vitro translated CREB cDNA was the same as that of band A; and 3) the migration of in vitro translated ATF-1 and CREB cDNAs,
after mixing, was the same as that of band B (data not
shown).2 Since one of the anti-ATF-1
antibodies (product sc-270x; Fig. 4, lane 2) cross-reacts
somewhat with CREB-1 according to the manufacturer's analysis, it is
consistent that not only band C, but also bands A and B were shifted
up. On the other hand, the other anti-ATF-1 antibody (product sc-243x)
specifically affects the migration of ATF-1 homodimers, but not that of
the ATF-1/CREB heterodimer in the gel mobility shift analysis (data not
shown). It is therefore consistent that only band C was shifted up with this antibody. Band D was consistently faint as compared with the other
bands. In addition, the antibodies used in these experiments had no
effect on the migration of band D. At this time, the composition of
band D has not been determined.
Binding Activity Comparison between Nuclear Extracts from Different
Sources
To compare the binding activity among normal thymocytes,
RadLV-infected thymocytes, and RadLV-induced thymoma cell lines, the
protein concentration of each nuclear extract was carefully measured
simultaneously and was repeated in triplicate. 1 µg of nuclear
protein from each preparation was used for gel mobility shift assay
(Fig. 5). In every preparation, bands A-D were observed as described above. In two preparations from RadLV-infected thymocyte tissue (Fig. 5, lanes 3 and 4) and two from the
RadLV-induced thymoma cell line (lanes 5 and 6),
H-2 BF1 binding activity was higher than that seen in two individual
preparations from normal thymocytes (lanes 1 and
2). Bands A-C were especially prominent. One preparation from
RadLV-infected thymocytes (Fig. 5, lane 3) showed the
highest binding activity when compared with other preparations. These
data were consistent with the Northern data (Fig. 6)
described below.
Fig. 6.
Northern analysis of RNA from normal
thymocytes, RadLV-infected thymocytes, and the RadLV-induced,
thymoma-derived cell line. A, H-2 IIa(sub), a broadly
cross-reactive cDNA clone to class I mRNA, was used as probe.
B, ATF-1, excised by BamHI and HindIII
from the ATF-1A clone, was used. C, -actin was used as
probe. Lane 1, RadLV-induced, thymoma-derived cell line RNA; lane 2, RNA from normal thymocytes of B10.T(6R) mice;
lanes 3-5, three preparations of RNA from RadLV-infected
B10.T(6R) thymocytes.
[View Larger Version of this Image (72K GIF file)]
Expression of ATF-1 in RadLV-infected Thymocytes and the
RadLV-induced, Tumor-derived Cell Line
The highly conserved MHC
class I probe hybridized to an mRNA of ~1.6 kb and showed that
the levels of H-2 mRNA are elevated in the RadLV-induced,
thymoma-derived cell line RNA (Fig. 6A, lane 1)
and in two out of three RNA samples extracted from RadLV-infected thymocytes (lanes 3-5). Two bands, corresponding to 2.4 and
1.5 kb, were detected by ATF-1A hybridization in the samples of
RadLV-infected murine thymocytes (Fig. 6B, lanes
3-5) and the RadLV-induced, thymoma-derived cell line (lane
1); these sizes are in agreement with the two cDNA clones
isolated representing differential use of polyadenylation signals (Fig.
6B, arrows). The levels of H-2 and ATF-1 mRNA
were increased both in RadLV-infected B10.T(6R) thymocytes (two of
three samples assayed) and in the cell line derived from a
RadLV-induced thymoma as compared with uninfected thymocytes (Fig.
2, A, lane 2; and B, lane
2). The level of -actin cDNA hybridization was relatively
consistent in all RNA preparations and demonstrates that the variances
seen above are not a result of varying RNA concentrations (Fig.
6C). The quantity of H-2 mRNA in different preparations
of RadLV-infected thymocytes very nearly parallels that of ATF-1
mRNA. The data therefore suggest that ATF-1 may be involved in the
up-regulation of transcription from the H-2Dd gene
after RadLV infection of thymocytes. One of three RNA
preparations from RadLV-infected B10.T(6R) thymocytes did not
show the increase in H-2 and ATF-1 mRNA levels (Fig. 2,
A, lane 3; and B, lane 3). This is consistent with the fact that usually ~70% of
thymocyte preparations from individual RadLV-infected B10.T(6R)
mice show increases in H-2 expression on the surface as measured by
fluorescence-activated cell sorting analysis, while the other 30% of
the preparations do not (data not shown).
Cotransfection Assays
To determine whether ATF-1 could
activate transcription of the H-2Dd gene in
vivo, F9 cells were transfected with either  65CAT or  122CAT reporter plasmids with or without expression vectors encoding the catalytic subunit of the cAMP-dependent
protein kinase and ATF-1 as described above. As shown in Fig.
7B, the  65CAT and  122CAT plasmids
contain sequences found 5 of the mouse H-2Dd gene
from positions 65 to +20 and from positions 122 to +20, respectively. The latter therefore includes the H-2 BF1 motif (TGACGCG,
from positions 99 to 93), while the former does not. In Fig.
7A, the induction index was calculated as follows: the experimental chloramphenicol acetyltransferase value was divided by the
value for the  65CAT reporter plasmid and antisense ATF-1 expression plasmid without the cAMP-dependent protein
kinase plasmid (the first bar in Fig. 7A) in each
experiment. Data are shown as the means ± S.D. of four
independent experiments. The  65CAT reporter plasmid showed only
small increases (<2.5-fold). The  122CAT reporter plasmid plus
pRc/RSV/ATF-1 with kinase showed an 8.5-fold increase on average,
whereas the  122CAT reporter plasmid plus pRc/RSV/ATF-1 without
kinase and the  122CAT reporter plasmid plus pRc/RSV/1-FTA
(antisense) showed a <3.0-fold increase on average. The combination of
ATF-1 and the cAMP-dependent protein kinase expression
plasmids with the  122CAT reporter plasmid produced a response that
was significantly greater than that produced by other combinations.
This is consistent with the report that ATF-1 activates transcription
in response to cAMP-dependent protein kinase A (52).
Fig. 7.
A, ATF-1 can activate a chloramphenicol
acetyltransferase reporter plasmid containing the H-2 BF1 motif. F9
cells were cotransfected with reporter plasmid (either  65CAT or
 122CAT) and ATF-1 expression plasmid (either ATF-1 or
1-FTA in A, sense or antisense direction, respectively) with or without the cAMP-dependent protein
kinase plasmid (PKA in A) as described under
"Materials and Methods." Levels of acetylated chloramphenicol were
quantitated using the NIH Image program (Version 1.60) and corrected
for -galactosidase activity to normalize for transfection
efficiency. The induction index shows induction relative to the value
of the  65CAT reporter plasmid and the antisense ATF-1 expression
plasmid without the cAMP-dependent protein kinase plasmid
in each experiment. Indicated are the means ± S.D. of four
independent experiments. B, shown is a schematic
representation of the  65CAT and  122CAT reporter plasmids.
Plasmids  65CAT and  122CAT contain sequences 5 of the mouse
H-2Dd gene from positions 65 to +20 and from
positions 122 to +20, respectively, linked to the gene for
chloramphenicol acetyltransferase (CAT) (23). The
hatched box represents the H-2 BF1 motif (TGACGCG). Stippled boxes represent CAAT and TATA boxes.
[View Larger Version of this Image (21K GIF file)]
DISCUSSION
Early experiments in the RadLV system indicated the importance of
immunosurveillance in controlling tumorigenesis and the impact that
altered MHC expression has on the effectiveness of the immune response
of the host to virus-infected cells. Subsequently, investigations in
several other systems including RNA (AKR murine leukemia virus, Moloney
leukemia virus, and vesicular stomatitis virus) and DNA (herpes simplex
virus, SV40, adenovirus, and polyoma virus) tumor viruses also
demonstrated alterations in class I gene expression resulting from
viral infections and/or virus-mediated transformations (for review, see
Ref. 53). In general, elevation of class I gene expression has been
correlated with disease resistance. The picture that emerges from all
of these systems is that viral infection often leads to enhanced
transcription and MHC expression, while viral transformation leads to
decreased expression. The net result of these changes is highly
significant for the ability of the immune system to either eliminate or
fail to respond to virus-infected/transformed cells. It has been
established that viral antigens are presented to immune effector cells
in the context of histocompatibility antigens. Studies in the systems
mentioned above have led to the recognition that the quantitative
expression of MHC molecules is as important to the effectiveness of the
immune system as is the nature of the MHC molecule involved. One key goal is to define the mechanisms by which viruses alter expression of
MHC genes.
Our laboratory first demonstrated that in RadLV-infected cells,
increased cell-surface expression of H-2Dd antigen is a
result of elevated levels of transcription (10). The
cis-regulatory element was located through DNA footprinting analysis; the protein complex that recognized and interacted with this
sequence was termed H-2 BF1 and was shown to be composed of at least
two proteins, one of which had a molecular mass of ~27 kDa (6, 10).
The cis-element is of interest in that it has been found to
be perfectly conserved in the 5 -region of nine out of nine known
functional genes encoding murine transplantation antigens. Likewise,
the sequence is identical in the majority of primate MHC genes that
have been shown to be functional.
In the experiments described here, we have used the yeast one-hybrid
system to identify murine ATF-1 as being one component of H-2 BF1. H-2
BF1 is the thymus-specific transcriptional activator complex (54) that
recognizes sequences (5 -TGACGCG-3 ) 5 of the H-2Dd
gene. The molecular mass of ATF-1 approximates that of one component of
H-2 BF1 as estimated from previous UV photocross-linking studies (10).
Originally, ATF-1 was cloned by screening cDNA libraries with
double-stranded DNA probes containing the CRE (12, 13). The CRE binding
motif is known to be essential for the basal transcriptional activity
of many promoters (55, 56), and ATF-1 has been shown to be involved in
the expression of numerous genes, including calcitonin, Na,K-ATPase
1-subunit, and interleukin-1 (57-60). Our data show
that ATF-1 can bind both to the CRE binding motif and to the similar
H-2 BF1 motif. The observation that anti-ATF-1 antibody changes the
mobility of the H-2 BF1·DNA complex in gel mobility assays is
strongly supportive of the conclusion that ATF-1 is one component of
the H-2 BF1 complex. Northern analysis data show that the levels of H-2
mRNA in various preparations of RadLV-infected thymocyte RNA very
nearly parallel those of ATF-1 mRNA. Transfection experiments also
demonstrate that ATF-1 activates the reporter plasmid that contains the
H-2 BF1 motif, but not the plasmid without the H-2 BF1 motif. Thus, it
is also suggested that ATF-1 up-regulates the transcription of the
H-2Dd gene after RadLV infection of thymocytes. This
is the first evidence implicating ATF-1 in the transcriptional
regulation of class I MHC genes.
Previously, we demonstrated that the H-2 BF1 complex was composed of at
least two proteins with approximate molecular masses of 27 and 65 kDa
(6, 10). During the screening process for clones recognizing the H-2
BF1 binding motif, many clones were isolated that did not show homology
to ATF-1. Sequence data show that these isolates are the p65 subunit of
NF- B and that, in fact, the in vitro translated protein
product of these clones does associate with ATF-1 in
vitro.2 It has been shown that NF- B does, under
some circumstances, associate with other transcription factors such as
c-Jun and c-Fos (61), the Epstein-Barr virus bZIP transactivator
(BZLF1) (62), and CCAAT/enhancer-binding protein family members (63).
Although preliminary attempts to demonstrate the association between
ATF-1 and NF- B p65 in vivo have not been successful, the
possibility that, under certain circumstances, ATF-1 could associate
with NF- B in vivo is under investigation. While
conducting UV photocross-linking analysis, it was noted that detection
of the 27-kDa protein was very strong and consistent; detection of the
65-kDa protein required higher amounts of nuclear extracts and was more
variable from extract to extract. In some nuclear preparations, a
protein of ~35 kDa was also detected in addition to the 27-kDa
protein (data not shown). As mentioned above, we have found that the
H-2 BF1 complex is composed of at least three forms: the ATF-1
homodimer, CREB homodimer, and ATF-1/CREB
heterodimer.2 Murine CREB has a molecular mass of 37 kDa (64), and therefore, the 35-kDa protein detected in UV
photocross-linking analysis is most probably CREB.
FOOTNOTES
*
This work was supported by National Institutes of Health
Grant CA22247 (to D. M.). The computing resources were supported by
National Science Foundation Grant BIR-9318128.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pathology and
Kaplan Cancer Center, New York University Medical Center, 550 First
Ave., New York, NY 10016. Tel.: 212-263-5599; Fax: 212-263-8211.
1
The abbreviations used are: MHC, major
histocompatibility complex; RadLV, radiation leukemia virus; H-2 BF1,
H-2 binding factor 1; CRE, cyclic AMP-responsive element; ATF-1,
activation transcription factor 1; kb, kilobase pair(s); bp, base
pair(s); CREB, CRE-binding protein.
2
N. Ishiguro, G. D. Brown, and D. Meruelo,
manuscript in preparation.
ACKNOWLEDGEMENTS
We thank Dr. R. R. Reed for providing the
yWAM2 yeast strain and plasmid vectors (pRS315HIS and pPC86), Dr.
Michael Garabedian for helpful discussions in the use of yeast, Dr.
Lorraine J. Gudas for providing the F9 cell line, Brandi Levin for
injection of the mice, Dr. Iwona Stroynowski for providing the  65
and  122CAT plasmids, Dr. Richard A. Maurer for providing the
RSV-CHO-PKA-C version 2 plasmid, and Dr. Chris Pampeno for critical
comments during the preparation of this manuscript.
REFERENCES
-
Klein, J., Figueroa, F., and Nagy, Z. A.
(1983)
Annu. Rev. Immunol.
1,
119-142
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hood, L., Steinmetz, M., and Malissen, B.
(1983)
Annu. Rev. Immunol.
1,
529-568
[CrossRef][Medline]
[Order article via Infotrieve]
-
Meruelo, D., Nimelstein, S. H., Jones, P. P., Lieberman, M., and McDevitt, H. O.
(1978)
J. Exp. Med.
147,
470-487
[Abstract/Free Full Text]
-
Meruelo, D., Lieberman, M., Ginzten, N., Deak, B., and McDevitt, H. O.
(1977)
J. Exp. Med.
146,
1079-1087
[Abstract/Free Full Text]
-
Meruelo, D.
(1979)
J. Exp. Med.
149,
898-909
[Abstract/Free Full Text]
-
Brown, G. D., Nobunaga, T., Morris, D. R., and Meruelo, D.
(1991)
Res. Immunol.
142,
431-440
[CrossRef][Medline]
[Order article via Infotrieve]
-
Israel, A., Le Bail, O., Hatat, D., Piette, J., Kieran, M., Logeat, F., Wallach, D., Fellous, M., and Kourilsky, P.
(1989)
EMBO J.
8,
3793-3800
[Medline]
[Order article via Infotrieve]
-
Dey, A., Thornton, A. M., Lonergan, M., Weissman, S. M., Chamberlain, J. W., and Ozato, K.
(1992)
Mol. Cell. Biol.
12,
3590-3599
[Abstract/Free Full Text]
-
Saji, M., Moriarty, J., Ban, T., Kohn, L. D., and Singer, D. S.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1944-1948
[Abstract/Free Full Text]
-
Nobunaga, T., Brown, G. D., Morris, D. R., and Meruelo, D.
(1992)
J. Immunol.
149,
871-879
[Abstract]
-
Wang, M. M., and Reed, R. R.
(1993)
Nature
364,
121-126
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hai, T., Liu, F., Coukos, W. J., and Green, M. R.
(1989)
Genes Dev.
3,
2083-2090
[Abstract/Free Full Text]
-
Lee, M.-R., Chung, C.-S., Liou, M.-L., Wu, M., Li, W.-F., Hsueh, Y.-P., and Lai, M.-Z.
(1992)
J. Immunol.
148,
1906-1912
[Abstract]
-
Lieberman, M., Decleve, A., Ricciardi-Castagnoli, P., Boniver, J., Finn, O. J., and Kaplan, H. S.
(1979)
Int. J. Cancer
24,
168-177
[Medline]
[Order article via Infotrieve]
-
Bach, R. G., and Meruelo, D.
(1984)
J. Exp. Med.
160,
270-285
[Abstract/Free Full Text]
-
Treco, D. A.
(1990)
in
Current Protocols in Molecular Biology (Ausubel, F. M., ed), pp. 13.0.1-13.2.11, John Wiley & Sons, Inc., New York
-
Chomczynski, P., and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159
[Medline]
[Order article via Infotrieve]
-
Brown, G. D., and Meruelo, D.
(1989)
J. Immunogenet. (Oxf.)
16,
351-361
-
Brown, G. D., Choi, Y., Egan, G., and Meruelo, D.
(1988)
Immunogenetics
27,
239-251
[CrossRef][Medline]
[Order article via Infotrieve]
-
Steinmetz, M., Frelinger, J. G., Fisher, D., Hunkapiller, T., Pereira, D., Weissman, S. M., Uehara, H., Nathenson, S., and Hood, L.
(1981)
Cell
24,
125-134
[CrossRef][Medline]
[Order article via Infotrieve]
-
Cleveland, D. W., Lopata, M. A., MacDonald, R. J., Cowan, N. J., Rutter, W. J., and Kirschner, M. W.
(1980)
Cell
20,
95-105
[CrossRef][Medline]
[Order article via Infotrieve]
-
Dignam, J. D., Lebovitz, R. M., and Roeder, R. G.
(1983)
Nucleic Acids Res.
11,
1475-1489
[Abstract/Free Full Text]
-
Korber, B., Hood, L., and Stroynowski, I.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
3380-3384
[Abstract/Free Full Text]
-
Howard, P., Day, K. H., Kim, K. E., Richardson, J., Thomas, J., Abraham, I., Fleischmann, R. D., Gottesman, M. M., and Maurer, R. A.
(1991)
J. Biol. Chem.
266,
10189-10195
[Abstract/Free Full Text]
-
Gorman, C. M., Moffat, L. F., and Howard, B. H.
(1982)
Mol. Cell. Biol.
2,
1044-1051
[Abstract/Free Full Text]
-
Herbomel, P., Bourachot, B., and Yaniv, M.
(1984)
Cell
39,
653-662
[CrossRef][Medline]
[Order article via Infotrieve]
-
Steinmetz, M., Moore, K. W., Frelinger, J. G., Sher, B. T., Shen, F.-W., Boyse, E. A., and Hood, L.
(1981)
Cell
25,
683-692
[CrossRef][Medline]
[Order article via Infotrieve]
-
Watts, S., Davis, A. C., Gaut, B., Wheeler, C., Hill, L., and Goodenow, R. S.
(1989)
EMBO J.
8,
1749-1759
[Medline]
[Order article via Infotrieve]
-
Singer, D. S., Hare, J., Golding, H., Flaherty, L., and Rudikoff, S.
(1988)
Immunogenetics
28,
13-21
[CrossRef][Medline]
[Order article via Infotrieve]
-
Kimura, A., Israel, A., Le Bail, O., and Kourilsky, P.
(1986)
Cell
44,
261-272
[CrossRef][Medline]
[Order article via Infotrieve]
-
Fisher, D. A., Pecht, M., and Hood, L.
(1989)
J. Mol. Evol.
28,
306-312
[CrossRef][Medline]
[Order article via Infotrieve]
-
Lambracht, D., and Wonigeit, K.
(1995)
Immunogenetics
41,
375-379
[CrossRef][Medline]
[Order article via Infotrieve]
-
Kirisits, M. J., Kunz, H. W., Hassett, A. L. C., and Gill, T. J.
(1992)
Immunogenetics
35,
365-377
[Medline]
[Order article via Infotrieve]
-
Kirisits, M. J., Sawai, H., Kunz, H. W., and Gill, T.
(1994)
Immunogenetics
39,
301-315
[Medline]
[Order article via Infotrieve]
-
Kryspin-Sorensen, I., Johansen, T., and Kastern, W.
(1991)
Immunogenetics
33,
213-215
[CrossRef][Medline]
[Order article via Infotrieve]
-
Singer, D. S., and Ehrlich, R.
(1988)
Curr. Top. Microbiol. Immunol.
137,
148-154
[Medline]
[Order article via Infotrieve]
-
Frels, W. I., Bordallo, C., Bolding, H., Rosenberg, A., Rudikoff, S., and Singer, D. S.
(1990)
New Biol.
2,
1024-1033
[Medline]
[Order article via Infotrieve]
-
Messer, G., Zemmour, J., Orr, H. T., Parham, P., Weiss, E. H., and Girdlestone, J.
(1992)
J. Immunol.
148,
4043-4053
[Abstract]
-
Malissen, M., Malissen, B., and Jordan, B. R.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
893-897
[Abstract/Free Full Text]
-
Chorney, M. J., Sawada, I., Gillespie, G. A., Srivastava, R., Pan, J., and Weissman, S. M.
(1990)
Mol. Cell. Biol.
10,
243-253
[Abstract/Free Full Text]
-
Balas, A., Garcia-Sanchez, F., Gomez-Reino, F., and Vicario, J. L.
(1994)
Immunogenetics
39,
452
[Medline]
[Order article via Infotrieve]
-
N'Guyen, C., Sodoyer, R., Trucy, J., Strachan, T., and Jordan, B. R.
(1985)
Immunogenetics
21,
479-489
[CrossRef][Medline]
[Order article via Infotrieve]
-
Koller, B. H., Geraghty, D. E., Shimizu, Y., DeMars, R., and Orr, H. T.
(1988)
J. Immunol.
141,
897-904
[Abstract]
-
Geraghty, D. E., Koller, B. H., and Orr, H. T.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
9145-9149
[Abstract/Free Full Text]
-
Lemonnier, F. A., Dubreuil, P. C., Layet, C., Malissen, M., Bourel, D., Mercier, P., Jakobsen, B. K., Caillol, D. H., Svejgaard, A., Kourilsky, F. M., and Jordan, B. R.
(1983)
Immunogenetics
18,
65-77
[CrossRef][Medline]
[Order article via Infotrieve]
-
Schmidt, H., Gekeler, V., Haas, H., Engler-Blum, G., Steiert, I., Probst, H., and Muller, C. A.
(1990)
Immunogenetics
31,
245-252
[Medline]
[Order article via Infotrieve]
-
Strachan, T., Sodoyer, R., Damotte, M., and Jordan, B. R.
(1984)
EMBO J.
3,
887-894
[Medline]
[Order article via Infotrieve]
-
Sanger, F., Nicklen, S., and Coulson, A. R.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467
[Abstract/Free Full Text]
-
Birnstiel, M. L., Busslinger, M., and Strub, K.
(1985)
Cell
41,
349-359
[CrossRef][Medline]
[Order article via Infotrieve]
-
Simonsen, C. C., and Levinson, A. D.
(1983)
Mol. Cell. Biol.
3,
2250-2258
[Abstract/Free Full Text]
-
Meyer, T., and Habener, J. F.
(1993)
Endocr. Rev.
14,
269-290
[Abstract/Free Full Text]
-
Rehfuss, R. P., Walton, K. M., Loriaux, M. M., and Goodman, R. H.
(1991)
J. Biol. Chem.
266,
18431-18434
[Abstract/Free Full Text]
-
Brown, G. D., Pampeno, C., and Meruelo, D.
(1991)
in
Immunogenetics of the MH Complex (Srivastava, R., Ram, B. P., and Tyle, P., eds), pp. 268-308, VCH Publishers, Inc., New York
-
Brown, G. D., Ishiguro, N., and Meruelo, D.
(1994)
Allerg. Immunol. (Paris)
13,
59-67
-
Andrisani, O. M., Pot, D. A., Zhu, Z., and Dixon, J. E.
(1988)
Mol. Cell. Biol.
8,
1947-1956
[Abstract/Free Full Text]
-
Quinn, P. G., Wong, W. T., Magnuson, M. A., Shabb, J. B., and Granner, D. K.
(1988)
Mol. Cell. Biol.
8,
3467-3475
[Abstract/Free Full Text]
-
Chandra, G., Cogswell, J. P., Miller, L. R., Godlevski, M. M., Stinnett, S. W., Noel, S. L., Kadwell, S. H., Kost, T. A., and Gray, J. G.
(1995)
J. Immunol.
155,
4535-4543
[Abstract]
-
Feuerstein, N., Huang, D., Hinrichs, S. H., Orten, D. J., Aiyar, N., and Prystowsky, M. B.
(1995)
J. Immunol.
154,
68-79
[Abstract]
-
Kobayashi, M., and Kawakami, K.
(1995)
Nucleic Acids Res.
23,
2848-2855
[Abstract/Free Full Text]
-
Morita, T., Delarbre, C., Kress, M., Kourilsky, P., and Gachelin, G.
(1985)
Immunogenetics
21,
367-383
[CrossRef][Medline]
[Order article via Infotrieve]
-
Stein, B., Baldwin, A. S., Ballard, D. W., Greene, W. C., Angel, P., and Herrlich, P.
(1993)
EMBO J.
12,
3879-3891
[Medline]
[Order article via Infotrieve]
-
Gutsch, D. E., Holley-Guthrie, E. A., Zhang, Q., Stein, B., Blanar, M. A., Baldwin, A. S., and Kenney, S. C.
(1994)
Mol. Cell. Biol.
14,
1939-1948
[Abstract/Free Full Text]
-
Stein, B., Cogswell, P. C., and Baldwin, A. S.
(1993)
Mol. Cell. Biol.
13,
3964-3974
[Abstract/Free Full Text]
-
Ruppert, S., Cole, T. J., Boshart, M., Schmid, E., and Schutz, G.
(1992)
EMBO J.
11,
1503-1512
[Medline]
[Order article via Infotrieve]
-
Sher, B. T., Nairn, R., Coligan, J. E., and Hood, L. E.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
1175-1179
[Abstract/Free Full Text]
-
Duran, L. W., Horton, R. M., Birschbach, C. W., Chang-Miller, A., and Pease, L. R.
(1989)
J. Immunol.
142,
288-296
[Abstract]
-
Watts, S., Vogel, J. M., Harriman, W. D., Itoh, T., Stauss, H. J., and Goodenow, R. S.
(1987)
J. Immunol.
139,
3878-3885
[Abstract]
-
Weiss, E., Golden, L., Zakut, R., Mellor, A., Fahrner, K., Kvist, S., and Flavell, R. A.
(1983)
EMBO J.
2,
453-462
[Medline]
[Order article via Infotrieve]
-
Lee, D. R., Rubocki, R. J., Lie, W. R., and Hansen, T. H.
(1988)
J. Exp. Med.
168,
1719-1939
[Abstract/Free Full Text]
-
Schepart, B. S., Takahashi, H., Cozad, K. M., Murray, R., Ozato, K., Appella, E., and Frelinger, J. A.
(1986)
J. Immunol.
136,
3489-3495
[Abstract]
-
Arnold, B., Burgert, H.-G., Archibald, A. L., and Kvist, S.
(1984)
Nucleic Acids Res.
12,
9473-9487
[Abstract/Free Full Text]
-
Sodoyer, R., Damotte, M., Delovitch, T. L., Trucy, J., Jordan, B. R., and Strachan, T.
(1984)
EMBO J.
3,
879-885
[Medline]
[Order article via Infotrieve]
-
Weiss, E. H., Kuon, W., Dorner, C., Lang, M., and Riethmuller, G.
(1985)
Immunobiology
170,
367-380
[Medline]
[Order article via Infotrieve]
-
Gussow, D., Rein, R. S., Meijer, I., de Hoog, W., Seemann, G. H. A., Hochstenbach, F. M., and Ploegh, H. L.
(1987)
Immunogenetics
25,
313-322
[CrossRef][Medline]
[Order article via Infotrieve]
-
Isamat, M., Girdlestone, J., and Milstein, C.
(1990)
Nucleic Acids Res.
18,
6702
[Free Full Text]
-
Cereb, N., and Yang, S. Y.
(1994)
J. Immunol.
152,
3873-3883
[Abstract]
-
Pohla, H., Kuon, W., Tabaczewski, P., Doerner, C., and Weiss, E. H.
(1989)
Immunogenetics
29,
297-307
[CrossRef][Medline]
[Order article via Infotrieve]
-
Chertkoff, L. P., Herrera, M., Fainboim, L., and Satz, M. L.
(1991)
Hum. Immunol.
31,
153-158
[CrossRef][Medline]
[Order article via Infotrieve]
-
Vallejo, A. N., and Pease, L. R.
(1995)
J. Immunol.
154,
3912-3921
[Abstract]
-
Tibensky, D., and Delovitch, T. L.
(1990)
Immunogenetics
32,
210-213
[CrossRef][Medline]
[Order article via Infotrieve]
-
Srivastava, R., and Lambert, M. E.
(1991)
in
Immunogenetics of the MH Complex (Srivastava, R., Ram, B. P., and Tyle, P., eds), pp. 100-154, VCH Publishers, Inc., New York
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. K. Howcroft, J. D. Weissman, A. Gegonne, and D. S. Singer
A T Lymphocyte-Specific Transcription Complex Containing RUNX1 Activates MHC Class I Expression
J. Immunol.,
February 15, 2005;
174(4):
2106 - 2115.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. K. Howcroft, A. Raval, J. D. Weissman, A. Gegonne, and D. S. Singer
Distinct Transcriptional Pathways Regulate Basal and Activated Major Histocompatibility Complex Class I Expression
Mol. Cell. Biol.,
May 15, 2003;
23(10):
3377 - 3391.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ishizu, K. Sawai, H. Ikeda, T. Hirano, N. Ishiguro, and D. Meruelo
Transduction of a murine dominant negative activation transcription factor 1 increases cell surface expression of the class I MHC on a human epidermoid tumor cell line
Int. Immunol.,
February 1, 2000;
12(2):
161 - 168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Ishiguro, G. D. Brown, A. Ishizu, and D. Meruelo
The Regulation of Murine H-2Dd Expression by Activation Transcription Factor 1 and cAMP Response Element Binding Protein
J. Immunol.,
June 15, 1998;
160(12):
5907 - 5914.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|